drugset / Trial / NCT05974774
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
Phase 3
Recruiting
1600 enrolled
European Organisation for Research and Treatment of Cancer - EORTC
Cancer Trials Ireland · collabSpanish Oncology Genito-Urinary Group · collabUNICANCER · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study addresses the global topic of treatment optimization, i.e. achieving similar benefit while reducing the duration of treatment, hence hoping to decrease the burden of side-effects, improve quality-of life and reduce resource utilization. The primary goal of de-escalation is to investigate whether using an intermittent regime results in a similar OS to continuous treatment.
Timeline
- Start
- 2025-05-23
- Primary completion
- 2035-05-23
- Completion
- 2039-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | — | — |
| Subject | Apalutamide | Small molecule | — | — |
| Subject | Darolutamide | Other / unclassified | — | — |
| Subject | Enzalutamide | Other / unclassified | — | — |